Clinical trials
Hemophilia A With Inhibitor clinical trials
Below are recruiting hemophilia a with inhibitor clinical trials, each written for real people, not researchers. We’re tracking 12 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04647227RecruitingPhase 4
SEVENFACT® to reduce bleeding in hemophilia with inhibitors
This trial studies whether SEVENFACT® can reduce bleeding episodes in people with hemophilia A or B who have inhibitors (proteins that make standard treatments less effective). It also tests how well people can track bleeding and medicine use during the study.
Phoenix, ArizonaAges 12–100 - NCT06320626RecruitingPhase 4
Personalized emicizumab dosing for hemophilia A
This trial tests whether adjusting emicizumab (Hemlibra) doses based on your body's drug levels can safely maintain good bleed control in people with hemophilia A who have been on the drug for at least a year.
Nijmegen, GelderlandAges 1 year+ - NCT05802836Recruiting
Tracking an antibody response in severe hemophilia A on emicizumab
This trial studies how your body’s anti-factor VIII antibodies change while you are treated with emicizumab for severe hemophilia A. The goal is to better understand the immune response during treatment and whether it relates to how well therapy works.
Frankfurt am Main, HesseAges Any age - NCT07406139RecruitingPhase 4
PCC treatment for hemophilia A with inhibitors
This trial tests a clotting factor product called PCC (prothrombin complex concentrate) to treat bleeding episodes in people with hemophilia A who have developed inhibitors. It's for those who are 12–65 and have frequent joint bleeds.
Tianjin, Tianjin MunicipalityAges 12–65 - NCT06864975RecruitingPhase 4
Different doses of ADVATE for immune tolerance in boys with hemophilia A and inhibitors
This trial tests how different doses and schedules of the factor VIII medicine ADVATE can train the immune system to accept factor VIII again in boys with hemophilia A who have developed inhibitors. The goal is to find a better way to help their bodies stop blocking the treatment.
Beijing, Beijing MunicipalityAges birth–18 years - NCT05145127RecruitingPhase 3
Marstacimab follow-up study for people with hemophilia
This Phase 3 study looks at how well and how safely marstacimab works over a longer follow-up period. You may join if you already finished a related parent study for hemophilia, and you can keep up with frequent visits and lab tests.
Iowa City, IowaAges 1–74 - NCT05888870RecruitingPhase 4
Testing a treatment for hemophilia A with inhibitor antibodies
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
TianjinAges 14–65 - NCT04023019Recruiting
Hemophilia A trial for people with FVIII inhibitors
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
Atlanta, GeorgiaAges Any age - NCT05981274Recruiting
Bone health study of a long-acting factor VIII for hemophilia A
This study tests whether a long-acting factor VIII medicine (rFVIIIFc) helps protect the bones and joints of people with hemophilia A. If you have severe or moderate hemophilia with joint damage and are already on this treatment, you may be able to join.
Taipei, Neihu Dist.Ages Any age - NCT02453542Recruiting
Testing how blood-clotting is managed in hemophilia with inhibitors
This study looks at different ways to help blood clot in people with hemophilia who have developed inhibitors (proteins that stop standard clotting treatments from working). It may help doctors choose the safest, most effective clotting approach for these situations.
Solna, Stockholm CountyAges 7 years+ - NCT07414511Recruiting
Hemophilia A research study for pregnant families
This study follows pregnant people who carry a severe hemophilia A gene and their babies after birth. It looks at how hemophilia A is passed down and how it affects families, with the goal of improving understanding and care.
Seattle, WashingtonAges Any age - NCT07096349Recruiting
Chronic pain study in severe hemophilia A
This study looks at chronic pain in people with severe hemophilia A. It aims to understand pain better through questionnaires and joint health checks.
Oviedo, Principality of AsturiasAges 18 years+
Hear when a new Hemophilia A With Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hemophilia a with inhibitor?
- Yes. Clin2 currently lists 12 recruiting hemophilia a with inhibitor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hemophilia a with inhibitor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hemophilia a with inhibitor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.